(Q45395971)

English

SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector

scientific article published on 8 April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector (English)

1 reference

Europe PubMed Central

14 December 2017

vector-borne disease

0 references

0 references

1 reference

based on heuristic

inferred from title

vesicular stomatitis

1 reference

based on heuristic

inferred from title

author name string

Sagar U Kapadia

1

1 reference

Europe PubMed Central

14 December 2017

Ian D Simon

2

1 reference

Europe PubMed Central

14 December 2017

John K Rose

3

1 reference

Europe PubMed Central

14 December 2017

language of work or name

0 references

publication date

8 April 2008

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

376

1 reference

Europe PubMed Central

14 December 2017

1

1 reference

Europe PubMed Central

14 December 2017

165-172

1 reference

Europe PubMed Central

14 December 2017

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Development of a new vaccine for the prevention of Lassa fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Emerging respiratory viruses: challenges and vaccine strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

A novel coronavirus associated with severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Recombinant vesicular stomatitis viruses from DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

The interaction of antibody with the major surface glycoprotein of vesicular stornatitis virus II. Monoclonal antibodies to nonneutralizing and cross-reactive epitopes of Indiana and New Jersey serotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Bats are natural reservoirs of SARS-like coronaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

The Genome sequence of the SARS-associated coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Efficient selection for high-expression transfectants with a novel eukaryotic vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Analysis of the molecules involved in human T-cell leukaemia virus type 1 entry by a vesicular stomatitis virus pseudotype bearing its envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.03.002

7 January 2021

based on heuristic

inferred from DOI database lookup

Attenuated vesicular stomatitis viruses as vaccine vectors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18396306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18396306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/18396306

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.VIROL.2008.03.002

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45395971&oldid=2076549876"